Q2e: -2% organic growth, EBITA SEK 94m (-16% y-o-y) Keeping FY guidance should be supportive for est...
Redeye comments on Embracers Q1 2023/24 report, which showed stronger growth than expected (organic ...
Redeye endorses yesterday's news that Sprint Bioscience has licensed the global rights to its cancer...
Taaleri's Q2 EBIT of EUR 17.8m came in clearly ahead of our estimate and Refinitiv consensus, driven...
Agilyx is reporting its H1 2023 results on 22 August, for which we pencil in revenue of USD 9m (18% ...
Netcompany's performance in Q2 2023 was close to that in Q1 – solid for the non-Danish operation (al...
I dag offentliggjorde Midsummer sin delårsrapport för det andra kvartalet 2023.
I dag offentliggjorde Risk Intelligence sin delårsrapport för det andra kvartalet 2023.
Movinn announced on August 14th, that the company (as operator and tenant) has signed a long-term le...
Utvecklingen i linje med våra förväntningar Kvartalet var i stort som vi förväntat oss.
Redeye updates its estimates and fair value range after Physitrack’s stable Q2 2023 report, which ca...
Sales 31.7m (-2% vs. ABGSCe), EBIT 6.3m (ABGSCe 9.0m) Unspecified one-offs in quarter, we estimate a...
Q2 adj. EBITDA 6% above our estimates New '23 guidance, EUR 125-130m top line & 47-50% margin Share ...
Algo likely to start recovery by the end of '23e '23e-'25e sales down 12-6% '23e-'24e EV/EBITDA of 3...
Raute reports Q2 results on Aug 25. We see Q2 a bit soft but growth is set to continue next year wit...
Alisa Bank reports its H1 results on August 18th. The loan portfolio development YTD has been flat, ...
Netcompany has today released its Q2 2023 interim report, which at first glance looks slightly disap...
Redeye comments on Maximum Entertainment’s Q2-results where revenue came in slightly above our forec...
Redeye is encouraged to see a stabilisation in Sleep Cycle’s total number of subscribers, thanks to ...
We cut '23e-'25e EBIT by 22-2% Consumer confidence remains relatively low '23e-'24e EV/EBIT ~34x-10x...
